1010 / 1119
Next generation of clinical trials
based on IGABT + IGRT as RCT
- Hypothesis driven -
Comparative Trials on IGABT
vs. 2D
(randomized)
Dose
escalation
for advanced disease HR CTV (LC, OS)
Dose
de-escalation
for limited and favourable
advanced disease (good response,…) (Morb/QoL)
Para-aortic RT, Lymphnode Boost (NC, OS)
Systematic concomitant radiochemotherapy min. 5 cycl
for subgroups with high risk of distant metastases (OS)
Testing Dose/Volume constraints for Target and OARs
Biomarker investigation (Hypoxia, HPV, EGFR, VEGF..)